<DOC>
	<DOC>NCT00365716</DOC>
	<brief_summary>This study was conducted in 2 parts. Part A was a randomized, double-blind, placebo-controlled, multicenter, sequential dose-escalating evaluation. Part B was a randomized, double-blind (operating under in-house blinding procedures), placebo-controlled, multicenter, dose-ranging study.</brief_summary>
	<brief_title>Dose-Ranging Study of Quadrivalent Human Papillomavirus (HPV) (Types 6,11,16,18) L1 Virus-Like Particle (VLP) Vaccine (V501-007)(COMPLETED)</brief_title>
	<detailed_description />
	<mesh_term>Papillomavirus Infections</mesh_term>
	<mesh_term>Genital Diseases, Female</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy females 16 to 23 years of age Not pregnant at enrollment and must have agreed to use effective contraception through Month 7 of the study Lifetime history of 0 to 4 male sexual partners (individuals with whom penetrative sexual intercourse occurred) No prior receipt of an Human Papillomavirus (HPV) vaccine No receipt of inactivated or recombinant vaccines within 14 days prior to enrollment or receipt of live vaccines within 21 days prior to enrollment No prior abnormal Pap test showing squamous intraepithelial lesion (SIL) or biopsy showing cervical intraepithelial neoplasia (CIN) No prior history of genital warts or treatment for genital warts</criteria>
	<gender>Female</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>23 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>HPV 6/11/16/18 infection and related genital disease</keyword>
</DOC>